The stock of Senti Biosciences Inc. (SNTI) has seen a 26.63% increase in the past week, with a 1.82% gain in the past month, and a -20.69% decrease in the past quarter. The volatility ratio for the week is 8.36%, and the volatility levels for the past 30 days are at 10.30% for SNTI. The simple moving average for the last 20 days is 17.47% for SNTI’s stock, with a simple moving average of -21.34% for the last 200 days.
Is It Worth Investing in Senti Biosciences Inc. (NASDAQ: SNTI) Right Now?
The 36-month beta value for SNTI is at 2.98. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SNTI is 27.38M, and currently, shorts hold a 0.60% of that float. The average trading volume for SNTI on April 30, 2024 was 79.34K shares.
SNTI) stock’s latest price update
Senti Biosciences Inc. (NASDAQ: SNTI)’s stock price has soared by 22.67 in relation to previous closing price of 0.31. Nevertheless, the company has seen a gain of 26.63% in its stock price over the last five trading days. Zacks Investment Research reported 2023-12-26 that The FDA clears Senti Bio’s (SNTI) investigational new drug application for SENTI-202 for the treatment of relapsed/refractory hematologic malignancies, including acute myeloid leukemia. Stock rises.
Analysts’ Opinion of SNTI
Many brokerage firms have already submitted their reports for SNTI stocks, with Morgan Stanley repeating the rating for SNTI by listing it as a “Equal-Weight.” The predicted price for SNTI in the upcoming period, according to Morgan Stanley is $7.50 based on the research report published on October 07, 2022 of the previous year 2022.
SNTI Trading at 1.38% from the 50-Day Moving Average
After a stumble in the market that brought SNTI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -65.46% of loss for the given period.
Volatility was left at 10.30%, however, over the last 30 days, the volatility rate increased by 8.36%, as shares surge +2.03% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -13.40% lower at present.
During the last 5 trading sessions, SNTI rose by +18.70%, which changed the moving average for the period of 200-days by -49.13% in comparison to the 20-day moving average, which settled at $0.3237. In addition, Senti Biosciences Inc. saw -42.44% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for SNTI
Current profitability levels for the company are sitting at:
- -39.74 for the present operating margin
- -14.5 for the gross margin
The net margin for Senti Biosciences Inc. stands at -27.31. The total capital return value is set at -0.95. Equity return is now at value -95.50, with -61.76 for asset returns.
Based on Senti Biosciences Inc. (SNTI), the company’s capital structure generated 0.36 points at debt to capital in total, while cash flow to debt ratio is standing at -1.39.
Currently, EBITDA for the company is -61.52 million with net debt to EBITDA at -0.03. When we switch over and look at the enterprise to sales, we see a ratio of 7.4. The receivables turnover for the company is 0.14for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.62.
Conclusion
In conclusion, Senti Biosciences Inc. (SNTI) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
